Key result
Inotropes and inopressors, such as dobutamine and milrinone, are often utilized as first-line therapies for managing acute decompensated heart failure and cardiogenic shock.
Why the study?
Inotropes and inopressors are often first-line treatment in patients with cardiogenic shock, requiring a summary of their pharmacology, indications, and clinical data in acute decompensated heart failure and cardiogenic shock.
This review provides a summary of the pharmacology, indications, and contraindications of inotropes and inopressors for managing acute decompensated heart failure and cardiogenic shock.
Current first-line inotrope use in ADHF and shock warrants scrutiny; review leaves comparative outcomes open for prospective trials.
Inotropes and inopressors are often first-line treatment in patients with cardiogenic shock. We summarize the pharmacology, indications, and contraindications of dobutamine, milrinone, dopamine, norepinephrine, epinephrine, and levosimendan. We also review the data on the use of these medications for acute decompensated heart failure and cardiogenic shock in this article.
No takes yet. Share an insight, caveat, or question.
Nandkeolyar et al. (2021) studied this question. Inotropes and inopressors, such as dobutamine and milrinone, are often utilized as first-line therapies for managing acute decompensated heart failure and cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: